Skip to main content
Premium Trial:

Request an Annual Quote

Affy Says Sales Surpassed $100M in Q4 04, a 17-Percent Increase

NEW YORK, Jan. 5 (GenomeWeb News) - Affymetrix estimates it has generated more than $100 million in product-related revenues for the fourth quarter of 2004, a record for the company, the firm said today.


This represents a 17-percent increase over the $85.3 million in product-related revenues recorded for the same quarter a year ago.


Affymetrix also said it has $10 million worth of orders for products it plans to release within the next six months, including new SNP-genotyping arrays and automated instrumentation.


The company will release its formal financial results on Jan. 26 after the stock market closes.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.